Clinical Trials

Clinical Trial Overview

  • Pacritinib

    Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis:
    PAC203 is Phase 2 dose-finding study of pacritinib in patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis who have received prior ruxolitinib.

    The study is currently recruiting participants. Learn More

    Primary Myelofibrosis:
    Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis (PAC325): PERSIST-1 is a multicenter, randomized, controlled Phase 3 trial comparing the efficacy and safety of pacritinib with that of best available therapy in patients with primary myelofibrosis.

    This study is not recruiting participants. Learn More

    Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis:
    Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis with Thrombocytopenia (PAC326): PERSIST-2 is a multicenter, randomized, controlled Phase 3 trial comparing the efficacy and safety of pacritinib Versus Best Available Therapy in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis.

    This study is not recruiting participants. Learn More

  • Pixantrone

    Phase 3 Study For Treatment Of Aggressive B-Cell Non-Hodgkin Lymphoma Or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy And Are Not Eligible For Stem Cell Transplant.
    An ongoing randomized, controlled Phase 3 clinical trial, known as PIX-R or PIX306.

    This study is currently recruiting participants. Learn More

  • Tosedostat

     

    Phase 1/2 Study Of Cytarabine And Tosedostat In Acute Myeloid Leukemia Or High Risk Myelodysplastic Syndromes.

    This study is active but not recruiting participants. Learn More

You Are Leaving CTI BioPharma

You have selected a link to a third-party website. This link is provided solely as a convenience to you and not as an endorsement by CTI BioPharma of such third-party website. CTI BioPharma is not responsible for and does not make any representations regarding the accuracy of materials on such third-party site.

Continue to the Requested Site
Return to CTI BioPharma

Hello! We are pleased to announce that Cell Therapeutics has changed its name to

Enter Site